The FDA’s War Against the Truth on Ivermectin

An article in the Wall Street Journal last July outlined the potential value of ivermectin for Covid-19, and questioned the FDA’s attack on it.

Now, the authors provide insight into some of the systemic factors hampering the repurposing of generic drugs like ivermectin.

Read their article on the AIER website.